APA

Borman P. J., Chatfield M. J., Crowley E. L., Eckers C., Elder D. P., Francey S. W., Laures A. M. & Wolff J. (20090331). Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API). : Journal of pharmaceutical and biomedical analysis.

Chicago

Borman Phil J, Chatfield Marion J, Crowley Elizabeth L, Eckers Christine, Elder David P, Francey Scott W, Laures Alice M-F and Wolff Jean-Claude. 20090331. Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API). : Journal of pharmaceutical and biomedical analysis.

Harvard

Borman P. J., Chatfield M. J., Crowley E. L., Eckers C., Elder D. P., Francey S. W., Laures A. M. and Wolff J. (20090331). Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API). : Journal of pharmaceutical and biomedical analysis.

MLA

Borman Phil J, Chatfield Marion J, Crowley Elizabeth L, Eckers Christine, Elder David P, Francey Scott W, Laures Alice M-F and Wolff Jean-Claude. Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API). : Journal of pharmaceutical and biomedical analysis. 20090331.